The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.

ABSTRACT:

Background

The inhibition of Breast Cancer 1 (BRCA1) expression sensitizes breast and ovarian cancer cells to platinum chemotherapy. However, therapeutically relevant agents that target BRCA1 expression have not been identified. Our recent report suggested the potential of the histone deacetylase (HDAC) inhibitor, M344, to inhibit BRCA1 expression. In this study, we further evaluated the effect of M344 on BRCA1 mRNA and protein expression, as well as its effect on cisplatin-induced cytotoxicity in various breast (MCF7, T-47D and HCC1937) and ovarian (A2780s, A2780cp and OVCAR-4) cancer cell lines.

Results

With the addition of M344, the platinum-sensitive breast and ovarian cancer cell lines that displayed relatively high BRCA1 protein levels demonstrated significant potentia

SUBMITTER: Weberpals JI 

PROVIDER: S-EPMC3175148 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature